DPP4 and Sepsis: A retrospective cohort study by Alex E. Henney et al. demonstrated that GLP-1RAs are associated with significantly lower risks of pneumonia and severe sepsis in patients with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP-4is).